Rheumatoid Arthritis: Causes, Symptoms, and Progression

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which the immune system attacks the synovial lining of joints, producing persistent inflammation that can lead to irreversible structural damage. It affects an estimated 1.3 million adults in the United States, according to the American College of Rheumatology (ACR), making it one of the most prevalent inflammatory arthropathies managed within rheumatologic practice. Understanding how RA begins, how it progresses, and how it differs from other joint diseases is essential to timely diagnosis and appropriate disease management. This page covers the definition, pathophysiological mechanism, typical clinical presentations, and the decision boundaries that guide clinical classification.

Definition and scope

Rheumatoid arthritis is classified as a systemic autoimmune inflammatory arthritis, formally defined in criteria jointly published by the ACR and European Alliance of Associations for Rheumatology (EULAR). The 2010 ACR/EULAR classification criteria assign scores across four domains — joint involvement, serology, acute-phase reactants, and symptom duration — with a threshold score of 6 out of 10 required for classification as definite RA.

RA is distinct from osteoarthritis in both mechanism and target population. While osteoarthritis results from mechanical cartilage degradation and predominantly affects adults over 60, RA arises from autoimmune dysregulation and has a peak onset between ages 40 and 60, with women affected at approximately 2 to 3 times the rate of men (National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIAMS). The full scope of RA extends beyond joints: systemic manifestations can involve the lungs, cardiovascular system, eyes, and skin, contributing to elevated morbidity and reduced life expectancy when the disease is poorly controlled.

For a broader orientation to inflammatory joint conditions within rheumatologic practice, see the Rheumatology Authority home.

How it works

The core pathophysiology of RA centers on synovial inflammation driven by a breakdown in immune self-tolerance. In genetically susceptible individuals, environmental triggers — most strongly implicated is cigarette smoking — activate antigen-presenting cells that stimulate autoreactive T cells and B cells. These immune cells infiltrate the synovial membrane, forming a hyperplastic, invasive tissue called pannus. Pannus secretes matrix metalloproteinases and pro-inflammatory cytokines, principally tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which degrade cartilage and erode subchondral bone.

Two autoantibodies are closely associated with this process:

  1. Rheumatoid Factor (RF): An antibody directed against the Fc region of immunoglobulin G, present in approximately 70–80% of RA patients (ACR).
  2. Anti-cyclic citrullinated peptide antibody (anti-CCP): Directed against citrullinated proteins; more specific than RF for RA, with specificity exceeding 95% (NIAMS).

These biomarkers are central to serological diagnosis. Anti-CCP positivity can precede clinical symptoms by 5 to 10 years, suggesting a prolonged pre-clinical autoimmune phase before joint destruction becomes apparent. More detail on serological testing is available on the Anti-CCP and Rheumatoid Factor page.

Structural joint damage in RA follows a predictable pattern: synovitis → cartilage loss → marginal bone erosion → joint deformity. Without disease-modifying treatment, radiographic erosions are detectable in up to 70% of patients within 2 years of symptom onset (ACR 2021 RA Treatment Guidelines).

Common scenarios

RA presents across a spectrum of severity and joint distribution, but several clinical patterns recur consistently in practice.

Symmetrical polyarthritis of small joints is the most recognized presentation. The metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints of the fingers, and metatarsophalangeal (MTP) joints of the feet are typically affected bilaterally. The distal interphalangeal (DIP) joints are characteristically spared — a feature that distinguishes RA from psoriatic arthritis. The Osteoarthritis vs. Inflammatory Arthritis page elaborates on these distinctions.

Morning stiffness lasting more than 60 minutes is a hallmark symptom. Its duration correlates with the degree of synovial inflammation and is used clinically to gauge disease activity. Stiffness of shorter duration is more typical of degenerative joint disease.

Extra-articular manifestations occur in roughly 40% of RA patients (NIAMS):

Seronegative RA represents a distinct subset in which both RF and anti-CCP are absent. Seronegative patients generally experience a milder joint course but pose greater diagnostic challenges, often requiring differentiation from other inflammatory arthropathies through imaging and clinical observation over time.

Felty's syndrome is a severe, uncommon variant defined by the triad of RA, splenomegaly, and neutropenia, carrying elevated infection risk. Its management intersects with the regulatory framing of immunosuppressive protocols covered at Regulatory Context for Rheumatology.

Decision boundaries

Distinguishing RA from conditions that mimic it requires attention to specific diagnostic thresholds and comparative clinical features.

Feature Rheumatoid Arthritis Psoriatic Arthritis Osteoarthritis Gout
Joint distribution Symmetric, MCP/PIP Asymmetric, DIP common Weight-bearing joints First MTP, ankles
Autoantibodies RF, anti-CCP (70–80%) Typically seronegative Absent Absent
Crystal deposits Absent Absent Absent Monosodium urate
Morning stiffness >60 minutes Variable <30 minutes Not characteristic
Radiographic finding Marginal erosions Periostitis, pencil-in-cup Joint space narrowing, osteophytes Tophi, punched-out erosions

The ACR/EULAR 2010 classification criteria remain the reference standard for defining RA in research and clinical settings. A score of 6 or higher — accounting for the number and size of joints involved, seropositivity, elevated C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR), and symptoms persisting 6 weeks or longer — establishes classification.

Disease activity is formally measured using validated composite indices:

  1. DAS28 (Disease Activity Score using 28 joints): Incorporates tender joint count, swollen joint count, ESR or CRP, and patient global assessment.
  2. CDAI (Clinical Disease Activity Index): Excludes laboratory values, relying on joint counts and assessments alone.
  3. SDAI (Simplified Disease Activity Index): Adds CRP to CDAI components.

The ACR defines remission in RA as a SDAI score of 3.3 or lower, or a CDAI of 2.8 or lower, targets endorsed in the ACR's treat-to-target framework (ACR Treatment Guidelines).

RA management decisions hinge critically on disease activity category (remission, low, moderate, high) and the presence of poor prognostic factors: high-titer anti-CCP, elevated acute-phase reactants, early radiographic erosion, and functional limitation. These factors determine the threshold for escalating from conventional DMARDs to biologic therapies or JAK inhibitors.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)